HTB: issue 5 online (14 March 2018): Special CROI issue

This special edition of HTB includes the first reports from CROI 2018, with additional reports following in subsequent issues. 

Important themes this year included cure-related research, TB coinfection, PrEP and new antiretroviral drugs.

As usual, webcasts and conference material are already online.

Also, news that after more than a decade in development, the monoclonal antibody ibalizumab has been approved in the US as a treatment for multidrug resistant HIV.